Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord blood-derived NK cells with rituximab and ASCT for B-cell NHL
NCT03019640Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Aug 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of cord blood-derived expanded allogeneic natural killer cells in B-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2017; status: completed.
02
Drugs
cord blood-derived expanded allogeneic natural killer cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03019640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019640.